Brian T. Helfand, M.D., Ph.D.

Dr. Helfand first organized Personalized Prostate Cancer Clinic in the United States. Initiated in 2013, first to routinely implement genomic and genetic based information to help guide prostate cancer screening and treatment decisions. Dr. Helfand initially started genetic testing as research trial only basis. Data supported that should be offered routinely. Now clinically available test that we developed in partnership with partnership with Ambry genetics that directly assesses a man’s risk of prostate cancer. As part of this clinic offer genetic assessment that includes evaluation of family history and genetic testing for prostate cancer genetic risk score (GRS) and high penetrance genes (HPGs). The prostate cancer GRS can identify a population of 30-40% of individuals who are at increased risk of prostate cancer. Similarly, it can identify men who may be at decreased risk of the disease. This information is important to guide the timing and frequency of screening.